Endologix, Inc. engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA). Its products include AFX Endovascular AAA System, Nellix and Ovation. The company was founded in March 1992 and is headquartered in Irvine, CA.
Company profile
Ticker
ELGX, ELGXQ
Exchange
Website
CEO
John Onopchenko
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CARDIOVASCULAR DYNAMICS INC, RADIANCE MEDICAL SYSTEMS INC /DE/
SEC CIK
Corporate docs
Subsidiaries
CVD/RMS Acquisition Corp. • Nellix, Inc. • RMS/Endologix Sideways Merger Corp. • ELGX International Holdings • Endologix International Holdings B.V. • ELGX South Korea Ltd. • Endologix International B.V. • Endologix New Zealand Co. • Endologix Bermuda L.P. • Endologix Italia S.r.l. ...
IRS number
680328265
ELGX stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
5 Oct 20
EFFECT
Notice of effectiveness
5 Oct 20
EFFECT
Notice of effectiveness
5 Oct 20
EFFECT
Notice of effectiveness
5 Oct 20
EFFECT
Notice of effectiveness
5 Oct 20
EFFECT
Notice of effectiveness
5 Oct 20
EFFECT
Notice of effectiveness
5 Oct 20
EFFECT
Notice of effectiveness
5 Oct 20
EFFECT
Notice of effectiveness
5 Oct 20
EFFECT
Notice of effectiveness
5 Oct 20
Latest ownership filings
SC 13G/A
CORRIB CAPITAL MANAGEMENT, L.P.
1 Oct 20
4
Dan Lemaitre
17 Sep 20
4
Dan Lemaitre
19 Aug 20
4
GREGORY D WALLER
14 Aug 20
4
John Onopchenko
14 Aug 20
4
Timothy Nicholas Brady
14 Aug 20
4
Thomas Wilder
14 Aug 20
4
Matthew Thompson
14 Aug 20
4
Cynthia Buch Pinto
14 Aug 20
4/A
Cynthia Buch Pinto
14 Aug 20
Financial summary
Quarter (USD) | Jun 20 | Mar 20 | Sep 19 | Jun 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.70 mm | 19.70 mm | 19.70 mm | 19.70 mm | 19.70 mm | 19.70 mm |
Cash burn (monthly) | 7.51 mm | (no burn) | 5.78 mm | 4.52 mm | 7.33 mm | 3.51 mm |
Cash used (since last report) | 337.96 mm | n/a | 260.14 mm | 203.29 mm | 329.88 mm | 157.92 mm |
Cash remaining | -318.27 mm | n/a | -240.45 mm | -183.59 mm | -310.19 mm | -138.22 mm |
Runway (months of cash) | -42.4 | n/a | -41.6 | -40.6 | -42.3 | -39.4 |
Institutional ownership, Q2 2022
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 2.15 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Captrust Financial Advisors | 2.15 k | $0.00 |